News & Updates

Key Updates in MASLD/MASH 2025

Metabolic dysfunction–associated steatotic liver disease (MASLD)คือชื่อใหม่ของโรคตับคั่งไขมันแทน non-alcoholic fatty liver disease (NAFLD) การเปลี่ยนนิยามนี้มุ่งเน้นการค้นหาสาเหตุหลักของโรคที่เกี่ยวข้องกับความผิดปกติทางเมแทบอลิก ซึ่งจะช่วยสะท้อนกลไกของโรค เพิ่มความแม่นยำในการวินิจฉัยและรักษา อีกทั้งยังช่วยลดความรู้สึกเชิงลบจากคำว่า “fatty” และ “non-alcoholic” ที่อาจทำให้ผู้ป่วยรู้สึกถูกตีตราได้

MASLD ไม่เพียงส่งผลกระทบต่อตับเท่านั้น แต่ยังสัมพันธ์กับโรคหัวใจและหลอดเลือด (CVD) ซึ่งเป็นสาเหตุการเสียชีวิตอันดับต้น ๆ ของผู้ป่วยกลุ่มนี้ จึงจำเป็นต้องมีการคัดกรองและประเมินความเสี่ยงอย่างครอบคลุม โดยเฉพาะในกลุ่มที่มีภาวะตับแข็งหรือมะเร็งตับร่วมด้วย

Liver metastasis, tumour size predict recurrence in mRCC after surgery

In patients with synchronous metastatic renal cell carcinoma (mRCC), factors such as liver metastasis, increasing primary tumour size, and elevated preoperative C-reactive protein (CRP) predict the risk of first-year progression following cytoreductive nephrectomy and complete metastasectomy, suggests a recent study.

CORE model outperforms FIB-4 in predicting liver-related outcomes

A novel risk score, named Cirrhosis Outcome Risk Estimator (CORE), performs better than FIB-4 in predicting liver-related outcomes in the general population, a study has shown. This model is based on a flexible modelling approach and utilizes biomarkers that are easily accessible in primary care.

Even low alcohol intake detrimental to East Asian men with MASLD

Intake of even small amounts of alcohol appears to pose a significant health risk for East Asian men with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a South Korean nationwide cohort study.

Inherited risk predicts increases in fibrosis in MASLD patients

Genetic risk score (GRS), polygenic risk score-hepatic fat content (PRS-HFC), its adjusted version (PRS-5), and PNPLA3 genotypes alone show a significant relationship with increased fibrosis severity per decade in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

The use of direct oral anticoagulants (DOACs) appears to be safer than warfarin for patients with nonvalvular atrial fibrillation (AF) and liver cirrhosis (LC), suggests a study. This is particularly true to reducing the risk of major bleeding in those with Child-Pugh class A disease.

LTSG delivers durable weight loss, improves metabolic syndrome

Simultaneous liver transplantation (LT) and sleeve gastrectomy (SG) is effective in sustaining weight loss, managing diabetes and hypertension, and preventing recurrence of steatosis and possibly fibrosis compared with LT alone, suggests a study.

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Many patients with cirrhosis and acute kidney injury (AKI) need 2 days to show response to albumin treatment, a study has found. Therefore, reducing the duration of albumin therapy may result in overtreatment with terlipressin.

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

The addition of pembrolizumab to the combination of gemcitabine and cisplatin does not appear to worsen the health-related quality of life (HRQoL) in patients with advanced biliary tract cancer (BTC), results of the phase III KEYNOTE-966 study have shown.